ClinVar Miner

Submissions for variant NM_000051.3(ATM):c.8147T>C (p.Val2716Ala) (rs587782652)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 19
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Ambry Genetics RCV000132066 SCV000187129 likely pathogenic Hereditary cancer-predisposing syndrome 2020-08-13 criteria provided, single submitter clinical testing <span style="background-color:initial">The p.V2716A <span style="background-color:initial">variant (also known as c.8147T>C), located in coding exon 54 of the ATM <span style="background-color:initial">gene, results from a T to C substitution at nucleotide position 8147. The valine at codon 2716 is replaced by alanine, an amino acid with similar properties. This alteration has been reported together with second known pathogenic ATM mutations in multiple individuals with milder, "variant ataxia-telangiectasia" (Demuth I et al. Neurogenetics. 2011 Nov;12:273-82; M&eacute;neret A, Neurology. 2014 Sep;83:1087-95; Verhagen MM et al. Neurology. 2009 Aug;73:430-7; Lohmann E et al. J. Neurol. 2015 Jul;262:1724-7; van Os NJH et al. J. Med. Genet., 2019 May;56:308-316<span style="background-color:initial">). This alteration has also been reported in an individual with variant ataxia-telangiectasia who did not have an identified second ATM alteration (Byrd PJ et al. Br. J. Cancer. 2012 Jan;106:262-8). Additionally, this alteration was reported in three unrelated women with ataxia-telangiectasia and breast cancer (Reiman A et al. Br. J. Cancer. 2011 Aug;105:586-91; Mandigers C et al. Radiother Oncol. 2011 Apr;99:97-8). <span style="background-color:initial">This alteration has been associated with reduced ATM protein expression, decreased ATM kinase activity, and increased radiosensitivity (Demuth I et al. Neurogenetics. 2011 Nov;12:273-82; Scott SP et al. Proc. Natl. Acad. Sci. U.S.A. 2002 Jan;99:925-30). This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Based on the majority of available evidence to date, this variant is likely to be pathogenic.
GeneDx RCV000212079 SCV000209770 pathogenic not provided 2018-04-20 criteria provided, single submitter clinical testing This variant is denoted ATM c.8147T>C at the cDNA level, p.Val2716Ala (V2716A) at the protein level, and results in the change of a Valine to an Alanine (GTT>GCT). This variant has been observed in the compound heterozygous state in multiple individuals with atypical or later-onset ataxia telangiectasia (Hiel 2006, Verhagen 2009, Demuth 2011, Keimling 2011, M?neret 2014, Kuhm 2015, Lohmann 2015, van Os 2017). In addition, ATM Val2716Ala has been published in the heterozygous state in at least three individuals with early-onset breast cancer, one of whom also had a history of unexplained childhood onset choreoathetosis, oculocutaneous telangiectasias, and elevated serum alpha-fetoprotein (Mandigers 2011, Reiman 2011). Although this variant may express some level of kinase activity, it has been associated with reduced ATM protein expression, and transfected cells have exhibited reduced radiation-induced kinase activity (Scott 2002, Verhagen 2009, Demuth 2011, Reiman 2011). ATM Val2716Ala was not observed at a significant allele frequency in large population cohorts (Lek 2016). This variant is located in the kinase domain and the ATP-binding domain (Lavin 2004, Stracker 2013). In silico analysis, which includes protein predictors and evolutionary conservation, supports a deleterious effect. Based on currently available evidence, we consider ATM Val2716Ala to be pathogenic.
Counsyl RCV000169105 SCV000220304 likely pathogenic Ataxia-telangiectasia syndrome 2014-05-13 criteria provided, single submitter literature only
Invitae RCV000169105 SCV000260088 pathogenic Ataxia-telangiectasia syndrome 2020-11-01 criteria provided, single submitter clinical testing This sequence change replaces valine with alanine at codon 2716 of the ATM protein (p.Val2716Ala). The valine residue is highly conserved and there is a small physicochemical difference between valine and alanine. This variant is present in population databases (rs587782652, ExAC 0.02%). This variant has been reported in several individuals affected with ataxia-telangiectasia (A-T) (PMID: 16864838, 19535770, 21354641, 21965147), as well as in an individual with generalized dystonia (PMID: 2557216), and an individual with breast cancer (PMID: 26976419). This variant has been reported to segregate with another pathogenic variant in ATM in a single family with dystonia (PMID: 25957637). ClinVar contains an entry for this variant (Variation ID: 142700). Experimental studies have shown that this missense change reduces ATM kinase activity and increases radiosensitivity (PMID: 11805335). For these reasons, this variant has been classified as Pathogenic.
Color Health, Inc RCV000132066 SCV000682458 likely pathogenic Hereditary cancer-predisposing syndrome 2020-09-25 criteria provided, single submitter clinical testing This missense variant replaces valine with alanine at codon 2716 of the kinase domain of ATM protein. Computational prediction tool suggests that this variant may have deleterious impact on protein structure and function (internally defined REVEL score threshold ‚â•0.7, PMID: 27666373). A functional study has shown that the variant results in the loss of ATM kinase activity and increased radiosensitivity (PMID: 11805335). This variant has been reported in multiple individuals affected with breast cancer (PMID: 26681312, 26976419; Color internal data). This variant has been reported in individuals affected with classic ataxia telangiectasia (PMID: 31050087) and atypical, late-onset ataxia telangiectasia (PMID: 25957637, 16864838, 21354641, 19535770, 21965147, 30819809). This variant has been identified in 9/282750 chromosomes in the general population by the Genome Aggregation Database (gnomAD). Based on the available evidence, this variant is classified as Likely Pathogenic.
Human Genome Sequencing Center Clinical Lab, Baylor College of Medicine RCV000709709 SCV000839884 likely pathogenic Familial cancer of breast 2017-06-05 criteria provided, single submitter clinical testing This c.8147T>C (p.Val2716Ala) has previously been reported in compound heterozygous patients with ataxia telangiectasia most of them diagnosed in adulthood [PMID 19535770, 16864838, 21965147]. This variant is located in the kinase domain and in vitro data showed reduced kinase activity and lower ATM protein [PMID 11805335]. This variant was observed in 5 individuals at the heterozygous state in the ExAC database (http://exac.broadinstitute.org/variant/11-108205832-T-C). Valine at amino acid position 2716 of the ATM protein is conserved in mammals. While not validated for clinical use, computer-based algorithms SIFT and Polyphen-2 did not yield concordant predictions regarding the pathogenicity of the change. It is thus interpreted as a likely pathogenic variant. However, the estimated cancer risk for this variant has not been determined.
Women's Health and Genetics/Laboratory Corporation of America, LabCorp RCV000169105 SCV000918562 pathogenic Ataxia-telangiectasia syndrome 2018-09-10 criteria provided, single submitter clinical testing Variant summary: ATM c.8147T>C (p.Val2716Ala) results in a non-conservative amino acid change located in the Phosphatidylinositol 3-/4-kinase, catalytic domain of the encoded protein sequence. Four of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 3.2e-05 in 277104 control chromosomes (gnomAD). The variant, c.8147T>C, has been reported in the literature in multiple individuals affected with Ataxia-Telangiectasia (Demuth_2011, Hiel_2006, Lohmann_2015). These data indicate that the variant is very likely to be associated with disease. At least one publication reports experimental evidence evaluating an impact on protein function. The most pronounced variant effect results in <10% of normal activity (Scott_2001). Five ClinVar submission from other clinical diagnostic laboratories (evaluation after 2014) cite the variant as likely pathogenic/pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic.
Academic Department of Medical Genetics, University of Cambridge RCV000132066 SCV000992207 likely pathogenic Hereditary cancer-predisposing syndrome 2018-01-26 criteria provided, single submitter research Application of AMCG guidelines 2015. Used other ClinVar submission evidence where relevant. Loss of heterozygosity in tumours or immunohistochemistry abnormalities considered functional evidence of pathogenicity.
Institute of Human Genetics, University of Leipzig Medical Center RCV000709709 SCV001429219 pathogenic Familial cancer of breast 2019-08-08 criteria provided, single submitter clinical testing
Athena Diagnostics Inc RCV000212079 SCV001475572 pathogenic not provided 2020-03-21 criteria provided, single submitter clinical testing The frequency of this variant in the general population is consistent with pathogenicity. Found in at least one patient with expected phenotype for this gene. Predicted to have a damaging effect on the protein. In multiple individuals, this variant has been seen with a single recessive pathogenic variant in the same gene, suggesting this variant may also be pathogenic. Assessment of experimental evidence suggests this variant results in abnormal protein function.
Department of Molecular Diagnostics, Institute of Oncology Ljubljana RCV000709709 SCV001499609 likely pathogenic Familial cancer of breast 2020-04-02 criteria provided, single submitter clinical testing
Molecular Medicine for Neurodegenerative and Neuromuscular Diseases Unit,IRCCS Fondazione Stella Maris RCV000169105 SCV001519105 pathogenic Ataxia-telangiectasia syndrome 2021-01-04 criteria provided, single submitter research
Mayo Clinic Laboratories, Mayo Clinic RCV000212079 SCV001713587 pathogenic not provided 2020-10-07 criteria provided, single submitter clinical testing PS3, PS4, PM2, PM3, PP3, PP4, PP5
GeneReviews RCV000169105 SCV000328271 pathogenic Ataxia-telangiectasia syndrome 2016-10-27 no assertion criteria provided literature only
Institute of Human Genetics, Klinikum rechts der Isar RCV000169105 SCV001149689 pathogenic Ataxia-telangiectasia syndrome 2018-01-10 no assertion criteria provided clinical testing
Diagnostic Laboratory, Department of Genetics, University Medical Center Groningen RCV000212079 SCV001740397 pathogenic not provided no assertion criteria provided clinical testing
Medical Genetics Laboratory, Umraniye Training and Research Hospital,University of Health Sciences RCV001640164 SCV001860286 pathogenic Breast carcinoma 2021-09-12 no assertion criteria provided clinical testing
Clinical Genetics Laboratory, Department of Pathology,Netherlands Cancer Institute RCV000212079 SCV001906005 pathogenic not provided no assertion criteria provided clinical testing
Human Genetics - Radboudumc,Radboudumc RCV000212079 SCV001955835 pathogenic not provided no assertion criteria provided clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.